July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor
Jul 10, 2025, 20:08

Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor

Pashtoon Kasi, Medical Director at City of Hope, shared on LinkedIn:

“Published today JCOPO, American Society of Clinical Oncology (ASCO)

The 1st agnostic study of a PARP inhibitor:

LODESTAR: Rucaparib

Need to think about variants in Homologous Recombination Repair (HRR) Genes beyond canonical BRCA PALB2.

Novel insights. Years of effort.”

Pashtoon Kasi

Title: LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes

Authors: Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey I. Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B. Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss

Read full article.

Pashtoon Kasi